Trial Profile
Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2012
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 04 Apr 2012 Status changed from active, no longer recruiting to discontinued, as reported at the 103rd Annual Meeting of the American Association for Cancer Research.
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
- 29 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.